Get started

Crispr

CRISPR: Crunch time again CRISPR Therapeutics Short Term We look to Sell at 82.82 (stop at 88.85) Previous resistance located at 83.00. Short term oscillators have turned negative. Posted a Bearish Outside candle on the Daily chart. A lower correction is expected. Our profit targets will be 68.87 and 60.76 Resistance: 83.00 / 96.00 / 135.00 Support: 73.00 / 60.50 / 43.00 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NASDAQ:CRSPShort
by Saxo
CRISPR breaking free? CRISPR Therapeutics Short Term We look to Buy a break of 73.10 (stop at 68.66) Further upside is expected and we look to set longs in early trade. The trend of higher lows is located at 60.50. Previous resistance, now becomes support at 73.00. A higher correction is expected. Our profit targets will be 82.99 and 94.00 Resistance: 83.00 / 96.00 / 135.00 Support: 73.00 / 60.50 / 43.00 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NASDAQ:CRSPLong
by Saxo
Crunch time for Crisp (r) ?CRISPR Therapeutics Short Term - We look to Buy a break of 59.19 (stop at 54.06) Further upside is expected and we look to set longs in early trade. A bullish reverse Head and Shoulders has formed. A break of yesterdays high would confirm bullish momentum. A higher correction is expected. Although the anticipated move higher is corrective, it does offer ample risk/reward today. Our profit targets will be 70.94 and 79.82 Resistance: 60.00 / 70.95 / 80.00 Support: 58.00 / 50.00 / 42.00 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NASDAQ:CRSPLong
by Saxo
1
CRSP Crispr Trend Change PossibleThis is a daily chart of CRSP. As you can see, I marked the areas where high volume has occurred in the past. It's a little hard to see as I had to make the vertical lines almost transparent so you could see the candle and the volume I marked. In every recent case a high volume daily candle has marked a trend change. This may not be the case now, but from the looks of it, it would hard to be short after the bulls stepping up like this during a down trend.
NASDAQ:CRSPLong
by ttrending
$CRISPR Head & Shoulder and breach of the 100emaHello fellow traders. We are experiencing a respectable pullback on many names these past few days. CRISPR is one of them. This stock has actually been in correction for sometime now, which picked up pace after disappointing earnings last week. We may see more downside in the short term if the market continues the selloff but this company is definitely a buy in my opinion. They have very good prospects to become the main gene editing company in the business. I had actually been waiting for a dip to enter a position, which I did last Friday. I am adding more as it goes down. I am not expecting it to moon tomorrow (which it will not), but I think the correction on this one may be coming to an end sometime soon. Also, the fact that this is one of the top holdings of ARK investments gives me that extra reassurance to buy. TECHNICALS You can see that CRISPR formed a head and shoulder pattern and broke down a few days ago. Although the right shoulder is kind of malformed, there is enough symmetry between the top of the two shoulders for us to can consider this a head and shoulder. Today the price breached and closed below the 100ema, which hasn't happened since May 2020. We are now on support of the .618 fib level (AKA inverse Golden Ratio), which in theory is strong. If this support doesn't hold the next stop is most likely the 200ema, which at the time of this writing is very close to the .786 fib level. The price can obviously change directions anytime but many traders like you and me are looking at the same indicators so the 200ema is a good anchor point. The RSI is about to cross to oversold level, a zone it hasn't been since March 2020. At that time it didn't stay in oversold for too long (about 4 days or so). Although past action doesn't indicate future behavior the quick reversal of the RSI direction is a good precedent if you want to buy in or already own the stock. Additionally you can see that the OBV isgetting close to the trendline support (yes, we can trace trendlines on the OBV too). HOW TO TRADE If you want to enter for the long term you can start dollar cost averaging (like I did) or wait for a clearer signal of reversal if you are more conservative. You may look for a bounce from either the fib levels or the emas as well as wait for a MACD bullish cross over. To me, anything between the 100ema and 200ema is a buy on this one. Safe trades and good luck! => If you get anything out of this TA, please hit the like button and/or follow for updates and new publications.<= ***The ideas shared here are my opinion, not financial advise to place trades. Please do your own research before buying/selling stocks***
NASDAQ:CRSP
by Safe_Trades
7
Crispr - DNA/Gene editing Technical Analysis Since early December, we have had over a dozen tails on the purple up-trend arrow drawn in. The 50sma is now coming into play, as a break below that, could take us another 20% down to the 100sma. An appropriate level to exit the trade then, would be below the 50sma. There also horizontal support as we fill the gap. Important Note: Earnings are on February 10th; so be aware of this if you plan to enter the trade. Opinion I believe this company is the future of gene editing. Check out a documentary of the company on Netflix called Human Nature. *It is more about how Crispr (DNA modification) works, than how the company makes money. Enjoy your weekend, dorfmaester
NASDAQ:CRSPLong
by dorfmanmaster
Long-term Moon Shot | Editas MedicineEditas Medicine is a clinical stage genome editing company, With the help of CRISPR technology, it focuses on treating a range of serious diseases like: -Leber Congenital Amaurosis type 10 (Genetic form of vision loss that leads to blindness in childhood) - EDIT-101 has recently entered phase 1/2 trial for the treatment, the very first time an in vivo CRISPR treatment enters clinical trials which with positive results could instantly make Editas a leader in this new field! -Usher Syndrome 2A (Form of retinitis pigmentosa that also includes hearing loss) -Treats sickle cell diseases and beta-thalassemia (A blood disorder that reduces the production of hemoglobin) It is also -In collaboration with Juno Therapeutics to develop engineered T cells for cancer! -Agreement with Allergan Pharmaceuticals International Limited to innovate, discover and develop new gene editing medicines for a range of ocular disorder -Collaboration with Asklepios BioPharmaceutical to develop therapy to treat neurological diseases The company has a lot of potential ahead in upcoming years! Let's get more technical! UNDERVALUED, I believe now would be a good time to lock in a long term position due to those facts -Recently had a public offering of 3.5M at $66 per share (Jan 21st) -Pe Ratio -39x -Fair Value of $479.88 US -Fib Retracement to current lows indicates a potential entry for the long term -LONG TERM TIMEFRAME 1D LOOKS PROMISING AS WELL!
NASDAQ:EDITLong
by NineToFive
Is CRSP trading in a descending triangle or bull flag?Key Takeaways A descending triangle is a signal for traders to take a short position to accelerate a breakdown. A descending triangle is detectable by drawing trend lines for the highs and lows on a chart. A descending triangle is the counterpart of an ascending triangle, which is another trend line based chart pattern used by technical analysts. Bullish flag formations are found in stocks with strong uptrends. They are called bull flags because the pattern resembles a flag on a pole. The pole is the result of a vertical rise in a stock and the flag results from a period of consolidation. The flag can be a horizontal rectangle, but is also often angled down away from the prevailing trend. Another variant is called a bullish pennant, in which the consolidation takes the form of a symmetrical triangle. The shape of the flag is not as important as the underlying psychology behind the pattern. Basically, despite a strong vertical rally, the stock refuses to drop appreciably, as bulls snap up any shares they can get. The breakout from a flag often results in a powerful move higher, measuring the length of the prior flag pole. It is important to note that these patterns work the same in reverse and are known as bear flags and pennants. EOM.
NASDAQ:CRSPLong
by ScotianBot